BACKGROUND: After cardiopulmonary bypass (CPB), elaboration of cytokines, and subsequent induction of interstitial proteases, such as matrix metalloproteinases (MMPs), can result in a complex postoperative course. The serine protease inhibitor, aprotinin, which has been used in congenital heart surgery putatively for modulating fibrinolysis is now unavailable, necessitating the use of lysine analogues such as tranexamic acid (TXA). The present study tested the hypothesis that distinctly different plasma profiles of signaling molecules and proteases would be differentially affected after the administration of aprotinin or TXA in the context of congenital cardiac surgery and CPB. METHODS: Thirty-seven patients (age, 4.8 +/- 0.3 months) undergoing corrective surgery for ventricular septal defect and tetralogy of Fallot received either aprotinin (n = 22) or TXA (n = 15). Using a high throughput multiplex suspension immunoassay, plasma was serially quantified for cytokines and MMPs: before aprotinin or TXA (baseline), after separation from CPB, and 4, 12, 24, and 48 hours post-CPB. RESULTS: Tumor necrosis factor-alpha increased initially after CPB in both the aprotinin and TXA groups, but at 24 and 48 hours post-CPB was approximately 50% lower in the aprotinin group (p < 0.05). The IL-10 levels were threefold higher in the TXA group compared with the aprotinin group immediately post-CBP (p < 0.05). Plasma levels of MMP types associated with inflammation, MMP-8, and MMP-9, were twofold higher in the late post-CPB period in the TXA group when compared with the aprotinin group. CONCLUSIONS: After ventricular septal defect or tetralogy of Fallot repair in children, cytokine induction occurs, which is temporally related to the emergence of a specific MMP profile. Moreover, these unique findings demonstrated differential effects between the serine protease inhibitor aprotinin and the lysine analogue TXA with respect to cytokine and MMP induction in the early postoperative period. The different cytokine-proteolytic profile between these antifibrinolytics may in turn influence biologic processes in the postoperative period. 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
BACKGROUND: After cardiopulmonary bypass (CPB), elaboration of cytokines, and subsequent induction of interstitial proteases, such as matrix metalloproteinases (MMPs), can result in a complex postoperative course. The serine protease inhibitor, aprotinin, which has been used in congenital heart surgery putatively for modulating fibrinolysis is now unavailable, necessitating the use of lysine analogues such as tranexamic acid (TXA). The present study tested the hypothesis that distinctly different plasma profiles of signaling molecules and proteases would be differentially affected after the administration of aprotinin or TXA in the context of congenital cardiac surgery and CPB. METHODS: Thirty-seven patients (age, 4.8 +/- 0.3 months) undergoing corrective surgery for ventricular septal defect and tetralogy of Fallot received either aprotinin (n = 22) or TXA (n = 15). Using a high throughput multiplex suspension immunoassay, plasma was serially quantified for cytokines and MMPs: before aprotinin or TXA (baseline), after separation from CPB, and 4, 12, 24, and 48 hours post-CPB. RESULTS:Tumor necrosis factor-alpha increased initially after CPB in both the aprotinin and TXA groups, but at 24 and 48 hours post-CPB was approximately 50% lower in the aprotinin group (p < 0.05). The IL-10 levels were threefold higher in the TXA group compared with the aprotinin group immediately post-CBP (p < 0.05). Plasma levels of MMP types associated with inflammation, MMP-8, and MMP-9, were twofold higher in the late post-CPB period in the TXA group when compared with the aprotinin group. CONCLUSIONS: After ventricular septal defect or tetralogy of Fallot repair in children, cytokine induction occurs, which is temporally related to the emergence of a specific MMP profile. Moreover, these unique findings demonstrated differential effects between the serine protease inhibitor aprotinin and the lysine analogue TXA with respect to cytokine and MMP induction in the early postoperative period. The different cytokine-proteolytic profile between these antifibrinolytics may in turn influence biologic processes in the postoperative period. 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Authors: Carl L Backer; Angela M Kelle; Robert D Stewart; Sunitha C Suresh; Farah N Ali; Richard A Cohn; Roopa Seshadri; Constantine Mavroudis Journal: J Thorac Cardiovasc Surg Date: 2007-10-22 Impact factor: 5.209
Authors: Dean A Fergusson; Paul C Hébert; C David Mazer; Stephen Fremes; Charles MacAdams; John M Murkin; Kevin Teoh; Peter C Duke; Ramiro Arellano; Morris A Blajchman; Jean S Bussières; Dany Côté; Jacek Karski; Raymond Martineau; James A Robblee; Marc Rodger; George Wells; Jennifer Clinch; Roanda Pretorius Journal: N Engl J Med Date: 2008-05-14 Impact factor: 91.245
Authors: Dumbor L Ngaage; Alexander R Cale; Michael E Cowen; Steven Griffin; Levant Guvendik Journal: Ann Thorac Surg Date: 2008-10 Impact factor: 4.330
Authors: Emma Pirilä; Jarkko T Korpi; Timo Korkiamäki; Tiina Jahkola; Ana Gutierrez-Fernandez; Carlos Lopez-Otin; Ulpu Saarialho-Kere; Tuula Salo; Timo Sorsa Journal: Wound Repair Regen Date: 2007 Jan-Feb Impact factor: 3.617
Authors: Bruce H Dorman; Robert E Stroud; Michael M Wyckoff; James L Zellner; Don Botta; Amy H Leonardi; John S Ikonomidis; Francis G Spinale Journal: J Cardiovasc Pharmacol Date: 2008-04 Impact factor: 3.105
Authors: Ana Gutiérrez-Fernández; Masaki Inada; Milagros Balbín; Antonio Fueyo; Ana S Pitiot; Aurora Astudillo; Kenji Hirose; Michiko Hirata; Steven D Shapiro; Agnès Noël; Zena Werb; Stephen M Krane; Carlos López-Otín; Xose S Puente Journal: FASEB J Date: 2007-03-28 Impact factor: 5.191
Authors: Stephen A Olenchock; Peter H U Lee; Tamar Yehoshua; Sabina A Murphy; James Symes; George Tolis Journal: Ann Thorac Surg Date: 2008-08 Impact factor: 4.330
Authors: Jane W Newburger; Richard A Jonas; Janet Soul; Barry D Kussman; David C Bellinger; Peter C Laussen; Richard Robertson; John E Mayer; Pedro J del Nido; Emile A Bacha; Joseph M Forbess; Frank Pigula; Stephen J Roth; Karen J Visconti; Adre J du Plessis; David M Farrell; Ellen McGrath; Leonard A Rappaport; David Wypij Journal: J Thorac Cardiovasc Surg Date: 2008-02 Impact factor: 5.209
Authors: Andrea Székely; Erzsébet Sápi; Tamás Breuer; Miklós D Kertai; Gábor Bodor; Péter Vargha; András Szatmári Journal: Paediatr Anaesth Date: 2008-02 Impact factor: 2.556
Authors: Eric M Graham; Andrew M Atz; Jenna Gillis; Stacia M Desantis; A Lauren Haney; Rachael L Deardorff; Walter E Uber; Scott T Reeves; Francis X McGowan; Scott M Bradley; Francis G Spinale Journal: J Thorac Cardiovasc Surg Date: 2011-11-09 Impact factor: 5.209
Authors: Chih-Yuan Lin; Jeffery H Shuhaiber; Hugo Loyola; Hua Liu; Pedro Del Nido; James A DiNardo; Frank A Pigula Journal: PLoS One Date: 2015-05-08 Impact factor: 3.240